Iohexol - Generic Drug Details

What are the generic sources for iohexol and what is the scope of patent protection?

Iohexol is the generic ingredient in ten branded drugs marketed by Interpharma Praha As and Ge Healthcare, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for iohexol. Three suppliers are listed for this compound.

Summary for iohexol

US Patents:	0
Tradenames:	10
Applicants:	2
NDAs:	3
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	66
Patent Applications:	6,410
What excipients (inactive ingredients) are in iohexol?	iohexol excipients list
DailyMed Link:	iohexol at DailyMed

Recent Clinical Trials for iohexol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Alexander Flannery	Phase 4
St. Olavs Hospital	Phase 4

See all iohexol clinical trials

Pharmacology for iohexol

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

Medical Subject Heading (MeSH) Categories for iohexol

Contrast Media

Anatomical Therapeutic Chemical (ATC) Classes for iohexol

V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08A	X-RAY CONTRAST MEDIA, IODINATED
V08	CONTRAST MEDIA
V	Various

US Patents and Regulatory Information for iohexol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	OMNIPAQUE 350	iohexol	SOLUTION;INJECTION, ORAL	018956-004	Dec 26, 1985		RX	Yes	Yes
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994		DISCN	No	No
Ge Healthcare	OMNIPAQUE 350	iohexol	SOLUTION;INJECTION, ORAL	020608-003	Oct 24, 1995		RX	No	No
Interpharma Praha As	ORALTAG	iohexol	FOR SOLUTION;ORAL	205383-001	Mar 26, 2015		DISCN	No	No
Ge Healthcare	OMNIPAQUE 240	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-002	Dec 26, 1985		RX	Yes	Yes
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985		RX	Yes	Yes
Ge Healthcare	OMNIPAQUE 9	iohexol	SOLUTION;ORAL	018956-008	Apr 17, 2018		RX	Yes	Yes

Expired US Patents for iohexol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OMNIPAQUE 240	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-002	Dec 26, 1985	4,021,481
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994	4,396,597
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	4,250,113
Ge Healthcare	OMNIPAQUE 350	iohexol	SOLUTION;INJECTION, ORAL	018956-004	Dec 26, 1985	4,250,113
Ge Healthcare	OMNIPAQUE 180	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-001	Dec 26, 1985	4,396,597
Ge Healthcare	OMNIPAQUE 140	iohexol	INJECTABLE;INJECTION	018956-005	Nov 30, 1988	4,021,481
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	4,396,597

Iohexol Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Iohexol

Introduction

Iohexol, a non-ionic, water-soluble radiographic contrast agent, is widely used in medical imaging procedures such as angiography, computed tomography (CT) scans, and other diagnostic imaging methods. Here, we delve into the market dynamics and financial trajectory of iohexol, highlighting key trends, drivers, and forecasts.

Market Size and Growth

The global iohexol market has been experiencing significant growth. As of 2022, the market size was valued at around USD 1.5 billion and is projected to grow at a compound annual growth rate (CAGR) of approximately 6.9% from 2022 to 2032, reaching USD 2.9 billion by 2032[1].

Segmentation

By Product Type

The iohexol market is segmented based on product types such as 0.99, 0.98, and others. These different concentrations are tailored for various medical imaging needs, with the 350mg I/ml, 240mg I/ml, and 300mg I/ml concentrations being particularly prominent in the iohexol injection sales market[3].

By Application

Iohexol is primarily used as a contrast agent and diagnostic agent. Its applications include angiography, CT scans, and other radiographic procedures. The increasing demand for precise and high-resolution imaging is driving the growth of iohexol in these segments[4].

By Geography

The market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region has its own market dynamics, with Asia Pacific showing significant growth due to the expanding healthcare sector and increasing demand for diagnostic imaging[1][2].

Drivers of Growth

Increasing Demand for Diagnostic Imaging

The global healthcare sector's growth and the need for accurate diagnostic imaging are key drivers of the iohexol market. As the population ages and the incidence of chronic diseases increases, the demand for high-resolution imaging techniques rises, thereby boosting the demand for iohexol[4].

Technological Advancements

Advancements in medical imaging technologies, such as improved CT scanners and angiography equipment, have enhanced the efficacy and safety of iohexol, making it a preferred choice for radiologists and clinicians[2].

Expanding Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in emerging economies, is creating new opportunities for the iohexol market. Increased access to healthcare services and the establishment of new hospitals and clinics are driving the demand for diagnostic imaging agents like iohexol[1].

Market Challenges

Supply Chain Disruptions

Recent shortages of iohexol have highlighted the vulnerabilities in the pharmaceutical supply chain. Such disruptions can impact the availability of the drug, affecting its market dynamics and financial performance[5].

Regulatory Frameworks

Stringent regulatory requirements and the need for compliance can pose challenges for manufacturers. Ensuring the quality and safety of iohexol while navigating complex regulatory landscapes is crucial for market success[2].

Key Players

The iohexol market is dominated by several key players, including GE Healthcare, Bracco Imaging S.p.A., Bayer AG, Daiichi Sankyo Company, Limited, and others. These companies are investing in research and development to improve the efficacy and safety of iohexol, as well as expanding their market presence through strategic partnerships and acquisitions[2][3].

Financial Trajectory

Revenue Projections

The global iohexol market is expected to achieve significant revenue growth. For instance, the iohexol API market was valued at US$ 506.1 million in 2023 and is anticipated to reach US$ 885.3 million by 2030, with a CAGR of 6.9% during the forecast period[4].

Regional Performance

North America and Europe are currently the largest markets for iohexol, driven by advanced healthcare infrastructure and high demand for diagnostic imaging. However, the Asia Pacific region is expected to show the highest growth rate due to its rapidly expanding healthcare sector and increasing demand for medical imaging services[1][2].

Market Dynamics Analysis

Drivers and Restraints

The market dynamics are influenced by a combination of drivers and restraints. Drivers include the increasing need for diagnostic imaging, technological advancements, and expanding healthcare infrastructure. Restraints include supply chain disruptions, regulatory challenges, and competition from other contrast agents[2][4].

Opportunities and Challenges

Opportunities in the iohexol market include the growing demand in emerging markets and the potential for new applications in medical imaging. Challenges include managing supply chain risks, complying with regulatory requirements, and maintaining market share in a competitive environment[1][3].

Consumer Behavior and Economic Impact

Consumer Behavior

The demand for iohexol is largely driven by healthcare professionals and institutions. The preference for iohexol over other contrast agents is influenced by its safety profile, efficacy, and the availability of different concentrations for various imaging procedures[3].

Economic Impact

The growth of the iohexol market has a positive economic impact, particularly in regions with expanding healthcare sectors. It contributes to job creation, investment in healthcare infrastructure, and the overall economic development of these regions[1].

Conclusion

The iohexol market is poised for significant growth driven by increasing demand for diagnostic imaging, technological advancements, and expanding healthcare infrastructure. Despite challenges such as supply chain disruptions and regulatory complexities, the market is expected to achieve substantial revenue growth over the forecast period.

Key Takeaways

• The global iohexol market was valued at USD 1.5 billion in 2022 and is projected to reach USD 2.9 billion by 2032.
• The market is driven by the increasing need for diagnostic imaging and technological advancements.
• Key players include GE Healthcare, Bracco Imaging S.p.A., and Bayer AG.
• The Asia Pacific region is expected to show the highest growth rate.
• Supply chain disruptions and regulatory challenges are significant restraints.

FAQs

1. What is the primary use of iohexol in medical imaging? Iohexol is primarily used as a contrast agent in medical imaging procedures such as angiography and computed tomography (CT) scans to make blood vessels and tissues more visible.

2. What is the projected CAGR of the global iohexol market from 2022 to 2032? The global iohexol market is projected to grow at a CAGR of approximately 6.9% from 2022 to 2032[1].

3. Which region is expected to show the highest growth rate in the iohexol market? The Asia Pacific region is expected to show the highest growth rate due to its rapidly expanding healthcare sector and increasing demand for medical imaging services[1][2].

4. What are the main drivers of the iohexol market? The main drivers include the increasing need for diagnostic imaging, technological advancements, and expanding healthcare infrastructure[4].

5. Who are some of the key players in the iohexol market? Key players include GE Healthcare, Bracco Imaging S.p.A., Bayer AG, and Daiichi Sankyo Company, Limited[2][3].

Sources

1. KD Market Insights. Iohexol Market Size, Share, Growth, Trends And Future Outlook 2032. [Online]. Available: https://www.kdmarketinsights.com/reports/iohexol-market/989
2. Market Research Intellect. Iohexol(CAS 66108-95-0) Market Size, Scope And Forecast Report. [Online]. Available: https://www.marketresearchintellect.com/product/global-iohexolcas-66108-95-0-market/
3. Market Research Intellect. Iohexol Injection Sales Market Size And Forecast. [Online]. Available: https://www.marketresearchintellect.com/product/iohexol-injection-sales-market-size-and-forecast/
4. Valuates Reports. Global Iohexol API Market Research Report 2024. [Online]. Available: https://reports.valuates.com/market-reports/QYRE-Auto-22G10562/global-iohexol-api
5. Radiological Society of North America. Short-, Mid-, and Long-term Strategies to Manage the Shortage of Iohexol. [Online]. Available: https://pubs.rsna.org/doi/full/10.1148/radiol.221183